BioCentury | Apr 10, 2006
Finance

Ebb & Flow

...10.5%); OZ Master Fund (7.9%); Perseus-Soros Biopharmaceutical Fund (6.8%); Sequel (6.5%); Duquesne Capital (6.5%); and HealthCare Investment Partners...
BioCentury | Sep 19, 2005
Finance

Ebb & Flow

...analog of Bactroban mupirocin from GlaxoSmithKline (LSE:GSK; GSK). Investors in the D round were Duquesne; Healthcare Investment Partners...
BioCentury | Sep 12, 2005
Company News

Replidyne Inc board of directors update

...Replidyne Inc ., Louisville, Colo. Business: Infectious Appointed: Henry Wendt, founder and managing partner of Healthcare Investment Partners WIR...
BioCentury | Sep 9, 2005
Financial News

Replidyne raises $62.5 million

...Louisville, Colo.) raised $62.5 million in a series D round led by new investors Duquesne; Healthcare Investment Partners...
...and Quintiles Transnational Corp. also participated in the round. Aquilo Partners was the placement agent. Healthcare Investment Partners'...
Items per page:
1 - 4 of 4
BioCentury | Apr 10, 2006
Finance

Ebb & Flow

...10.5%); OZ Master Fund (7.9%); Perseus-Soros Biopharmaceutical Fund (6.8%); Sequel (6.5%); Duquesne Capital (6.5%); and HealthCare Investment Partners...
BioCentury | Sep 19, 2005
Finance

Ebb & Flow

...analog of Bactroban mupirocin from GlaxoSmithKline (LSE:GSK; GSK). Investors in the D round were Duquesne; Healthcare Investment Partners...
BioCentury | Sep 12, 2005
Company News

Replidyne Inc board of directors update

...Replidyne Inc ., Louisville, Colo. Business: Infectious Appointed: Henry Wendt, founder and managing partner of Healthcare Investment Partners WIR...
BioCentury | Sep 9, 2005
Financial News

Replidyne raises $62.5 million

...Louisville, Colo.) raised $62.5 million in a series D round led by new investors Duquesne; Healthcare Investment Partners...
...and Quintiles Transnational Corp. also participated in the round. Aquilo Partners was the placement agent. Healthcare Investment Partners'...
Items per page:
1 - 4 of 4